Skip to main content
Premium Trial:

Request an Annual Quote

Invivoscribe Claims Win in FLT3 Patent Case

NEW YORK (GenomeWeb News) – Invivoscribe Technologies today said that a German court has ruled in its favor in a patent dispute over FLT3 testing technology.

The San Diego-based firm said that the German District court in Munich found MLL Muenchner Leukaemielabor GmbH Laboratories guilty of infringing a patent held by Takara Bio and licensed exclusively to Invivoscribe. It also noted that the court declined to stay enforcement of its decision.

The patent, EP 959 132 B1, covers testing for internal tandem duplication mutations in the juxtamembrane region of FLT3. The presence of such mutations is associated with poor prognosis in acute myeloid leukemia patients.

Invivoscribe, which conducts testing in its labs in San Diego and in Germany, said the patents cover testing whether it is done by sequencing, by analysis of length, or by any other method.

Invivoscribe signed an expanded licensing deal with Takara Bio this past December covering FLT3 testing.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.